A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors
J. Thorac. Oncol., Available online 24 December 2021 | https://doi.org/10.1016/j.jtho.2021.11.025
Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer
J. Thorac. Oncol., Volume 4, Issue 7, July 2009, Pages 809-815 | https://doi.org/10.1097/JTO.0b013e3181a94af4
Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status
J. Thorac. Oncol., Volume 15, Issue 11, November 2020, Pages 1758-1766 | https://doi.org/10.1016/j.jtho.2020.06.018
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy
Ann. Oncol., Available online 5 July 2020 | https://doi.org/10.1016/j.annonc.2020.06.017
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
J. Clin. Oncol., Published online : December 06, 2019 | DOI: 10.1200/JCO.19.00457
관련인물
Interview
